Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database
Por:
Remon J, Isla D, Garrido P, de Castro J, Majem M, Viñolas N, Artal A, Carcereny E, García-Campelo MR, Lianes P, Provencio M, Juan O, Diz P, Blanco R, Lopez-Castro R, Maestu I, Vadell C and Felip E
Publicada:
1 dic 2017
Ahead of Print:
28 jun 2017
Resumen:
The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.
WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.
From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.
Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.
Filiaciones:
Remon J:
Medical Oncology Department, Hospital Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain
Isla D:
Medical Oncology Department, Instituto de Investigación Sanitaria Aragón, Hospital Clinico Universitario Lozano Blesa, Saragossa, Spain
Garrido P:
Medical Oncology Department, Hospital Ramón y Cajal, Madrid, Spain
de Castro J:
Medical Oncology Department, Hospital La Paz, Madrid, Spain
Majem M:
Medical Oncology Department, Hospital Sant Pau, Barcelona, Spain
Viñolas N:
Medical Oncology Department, Hospital Clinic, Barcelona, Spain
Artal A:
Medical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain
Carcereny E:
Medical Oncology Department, Hospital Germans Trias i Pujol ICO-Badalona, Barcelona, Spain
García-Campelo MR:
Medical Oncology Department, Complexo Hospitalario Universitatio A Coruña, Coruña, Spain
Lianes P:
Medical Oncology Department, Hospital de Mataró, Mataró, Barcelona, Spain
Provencio M:
Medical Oncology Department, Hospital Puerta de Hierro, Madrid, Spain
:
Medical Oncology Department, Hospital Universitari Politècnic La Fe, Valencia, Spain
Diz P:
Medical Oncology Department, Hospital de León, León, Spain
Blanco R:
Medical Oncology Department, Consorci Sanitari de Terrassa, Hospital de Terrassa, Terrassa, Barcelona, Spain
Lopez-Castro R:
Medical Oncology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
:
Medical Oncology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Vadell C:
Medical Oncology Department, Hospital de Manacor, Menorca, Spain
Felip E:
Medical Oncology Department, Hospital Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
|